{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T02:08:40Z","timestamp":1763172520639,"version":"3.45.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Sichuan Mingtong Tianxia Tea Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-025-09235-5","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T16:41:49Z","timestamp":1763138509000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of Jinhua instant dark tea in patients with type 2 diabetes mellitus: study protocol for a multicenter, open-label, randomized controlled trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Ningsu","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yana","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daomei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengnan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dejiao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiajie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"9235_CR1","doi-asserted-by":"publisher","first-page":"838027","DOI":"10.3389\/fendo.2022.838027","volume":"13","author":"S Safiri","year":"2022","unstructured":"Safiri S, Karamzad N, Kaufman JS, Bell AW, Nejadghaderi SA, Sullman MJM, et al. Prevalence, deaths and disability-adjusted-life-years (DALYs) due to type 2 diabetes and its attributable risk factors in 204 countries and territories, 1990\u20132019: results from the Global Burden of Disease Study 2019. Front Endocrinol (Lausanne). 2022;13:838027.\u00a0","journal-title":"Front Endocrinol (Lausanne)"},{"key":"9235_CR2","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"9235_CR3","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1186\/s12889-020-09502-x","volume":"20","author":"J Liu","year":"2020","unstructured":"Liu J, Ren ZH, Qiang H, Wu J, Shen M, Zhang L, et al. Trends in the incidence of diabetes mellitus: results from the Global Burden of Disease Study 2017 and implications for diabetes mellitus prevention. BMC Public Health. 2020;20(1):1415.","journal-title":"BMC Public Health"},{"issue":"24","key":"9235_CR4","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1001\/jama.2021.22208","volume":"326","author":"L Wang","year":"2021","unstructured":"Wang L, Peng W, Zhao Z, Zhang M, Shi Z, Song Z, et al. Prevalence and treatment of diabetes in China, 2013\u20132018. JAMA. 2021;326(24):2498\u2013506.","journal-title":"JAMA"},{"issue":"9","key":"9235_CR5","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41574-022-00690-7","volume":"18","author":"D Tomic","year":"2022","unstructured":"Tomic D, Shaw JE, Magliano DJ. The burden and risks of emerging complications of diabetes mellitus. Nat Rev Endocrinol. 2022;18(9):525\u201339.","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"9235_CR6","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa012512","volume":"346","author":"WC Knowler","year":"2002","unstructured":"Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393\u2013403.","journal-title":"N Engl J Med"},{"issue":"2","key":"9235_CR7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255\u2013323.","journal-title":"Eur Heart J"},{"issue":"04","key":"9235_CR8","first-page":"315","volume":"13","author":"Society CD","year":"2021","unstructured":"Society CD. Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition). Chin J Diabetes Mellit. 2021;13(04):315\u2013409.","journal-title":"Chin J Diabetes Mellit"},{"issue":"Suppl 1","key":"9235_CR9","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.2337\/dc19-S005","volume":"42","author":"AD Association","year":"2019","unstructured":"Association AD. 5. Lifestyle management: standards of medical care in diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S46-s60.","journal-title":"Diabetes Care"},{"issue":"10","key":"9235_CR10","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.2337\/dci21-0034","volume":"44","author":"MC Riddle","year":"2021","unstructured":"Riddle MC, Cefalu WT, Evans PH, Gerstein HC, Nauck MA, Oh WK, et al. Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetes Care. 2021;44(10):2438\u201344.","journal-title":"Diabetes Care"},{"issue":"5","key":"9235_CR11","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.3390\/jcm12051981","volume":"12","author":"E Piragine","year":"2023","unstructured":"Piragine E, Petri D, Martelli A, Calderone V, Lucenteforte E. Adherence to oral antidiabetic drugs in patients with type 2 diabetes: systematic review and meta-analysis. J Clin Med. 2023;12(5):1981.","journal-title":"J Clin Med"},{"issue":"2","key":"9235_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11892-023-01532-0","volume":"24","author":"K Gow","year":"2024","unstructured":"Gow K, Rashidi A, Whithead L. Factors influencing medication adherence among adults living with diabetes and comorbidities: a qualitative systematic review. Curr Diab Rep. 2024;24(2):19\u201325.","journal-title":"Curr Diab Rep"},{"issue":"05","key":"9235_CR13","first-page":"316","volume":"40","author":"Y Hu","year":"2019","unstructured":"Hu Y. Research progress on main active constituents and healthcare function of Ya\u2019an Tibetan tea. Sci Technol Food Ind. 2019;40(05):316\u201321.","journal-title":"Sci Technol Food Ind"},{"issue":"5","key":"9235_CR14","doi-asserted-by":"publisher","first-page":"e27145","DOI":"10.1016\/j.heliyon.2024.e27145","volume":"10","author":"J Deng","year":"2024","unstructured":"Deng J, Luo K, Xia C, Zhu Y, Xiang Z, Zhu B, et al. Phytochemical composition of Tibetan tea fermented by Eurotium cristatum and its effects on type 1 diabetes mice and gut microbiota. Heliyon. 2024;10(5):e27145.","journal-title":"Heliyon."},{"key":"9235_CR15","doi-asserted-by":"publisher","first-page":"112520","DOI":"10.1016\/j.foodres.2023.112520","volume":"165","author":"Y Yuan","year":"2023","unstructured":"Yuan Y, He J, Tang M, Chen H, Wei T, Zhang B, et al. Preventive effect of Ya\u2019an Tibetan tea on obesity in rats fed with a hypercaloric high-fat diet revealed by gut microbiology and metabolomics studies. Food Res Int. 2023;165:112520.","journal-title":"Food Res Int"},{"issue":"18","key":"9235_CR16","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.3390\/nu15183862","volume":"15","author":"J Liu","year":"2023","unstructured":"Liu J, Wang X, Zhu Y, Deng H, Huang X, Jayavanth P, et al. Theabrownin from dark tea ameliorates insulin resistance via attenuating oxidative stress and modulating IRS-1\/PI3K\/Akt pathway in HepG2 cells. Nutrients. 2023;15(18):3862.","journal-title":"Nutrients"},{"issue":"4","key":"9235_CR17","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1039\/D1FO03374C","volume":"13","author":"S Yue","year":"2022","unstructured":"Yue S, Shan B, Peng C, Tan C, Wang Q, Gong J. Theabrownin-targeted regulation of intestinal microorganisms to improve glucose and lipid metabolism in Goto-Kakizaki rats. Food Funct. 2022;13(4):1921\u201340.","journal-title":"Food Funct"},{"key":"9235_CR18","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.carbpol.2016.08.022","volume":"153","author":"G Chen","year":"2016","unstructured":"Chen G, Yuan Q, Saeeduddin M, Ou S, Zeng X, Ye H. Recent advances in tea polysaccharides: extraction, purification, physicochemical characterization and bioactivities. Carbohydr Polym. 2016;153:663\u201378.","journal-title":"Carbohydr Polym"},{"issue":"01","key":"9235_CR19","first-page":"63","volume":"49","author":"J Dai","year":"2023","unstructured":"Dai J, Yang TB, Chen LW, Deng SW, Cao Y, Hao JL, et al. Effects of Tibetan tea water extract on blood lipids and gut flora in mice fed with high sugar and fat diet. China Measure Test. 2023;49(01):63\u201370.","journal-title":"China Measure Test"},{"issue":"04","key":"9235_CR20","first-page":"151","volume":"40","author":"JN Zhu","year":"2015","unstructured":"Zhu JN, Zhang TQ, Li SZ, Xu JY, Lv XH. Effect of Tibetan tea on weight loss and blood lipid-lowering in rats. Food Sci Technol. 2015;40(04):151\u20134.","journal-title":"Food Sci Technol"},{"issue":"04","key":"9235_CR21","first-page":"168","volume":"38","author":"XH Lv","year":"2017","unstructured":"Lv XH, Xu JY, Sun R, Wang JY. Human trial of health effects of Tibetan tea. Food Res Dev. 2017;38(04):168\u201371.","journal-title":"Food Res Dev"},{"issue":"8","key":"9235_CR22","doi-asserted-by":"publisher","first-page":"102581","DOI":"10.1016\/j.dsx.2022.102581","volume":"16","author":"DL Tahapary","year":"2022","unstructured":"Tahapary DL, Pratisthita LB, Fitri NA, Marcella C, Wafa S, Kurniawan F, et al. Challenges in the diagnosis of insulin resistance: focusing on the role of HOMA-IR and tryglyceride\/glucose index. Diabetes Metab Syndr. 2022;16(8):102581.","journal-title":"Diabetes Metab Syndr"},{"key":"9235_CR23","unstructured":"Society. CD, Care. NOfPD. National handbook for the prevention and control of diabetes in primary care (2022). Chin J Intern Med. 2022;61(7):717-48."},{"issue":"11","key":"9235_CR24","doi-asserted-by":"publisher","first-page":"4051","DOI":"10.1002\/ptr.7572","volume":"36","author":"P Wang","year":"2022","unstructured":"Wang P, Ma XM, Geng K, Jiang ZZ, Yan PY, Xu Y. Effects of Camellia tea and herbal tea on cardiometabolic risk in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2022;36(11):4051\u201362.","journal-title":"Phytother Res"},{"key":"9235_CR25","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1038\/ijo.2008.87","volume":"32 Suppl 3","author":"KJ Rothman","year":"2008","unstructured":"Rothman KJ. BMI-related errors in the measurement of obesity. Int J Obes (Lond). 2008;32 Suppl 3:S56-9.","journal-title":"Int J Obes (Lond)"},{"key":"9235_CR26","unstructured":"Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. WHO; 1995. Report No.: 0512\u20133054 (Print)."},{"issue":"7","key":"9235_CR27","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1097\/HJH.0000000000002843","volume":"39","author":"GS Stergiou","year":"2021","unstructured":"Stergiou GS, Palatini P, Parati G, O\u2019Brien E, Januszewicz A, Lurbe E, et al. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens. 2021;39(7):1293\u2013302.","journal-title":"J Hypertens"},{"key":"9235_CR28","unstructured":"World Health Organization. Body mass index (BMI). In: Global Health Observatory (GHO) data. 2025. https:\/\/www.who.int\/data\/gho\/data\/themes\/topics\/topic-details\/GHO\/body-mass-index?form=MG0AV3. Accessed 25 Aug 2025."},{"key":"9235_CR29","unstructured":"United Nations Department of Economic and Social Affairs Population Division. Introduction: measures of population ageing. In: World population ageing 2019. 2020. https:\/\/www.un.org\/en\/development\/desa\/population\/publications\/pdf\/ageing\/WorldPopulationAgeing2019-Report.pdf. Accessed 25 Aug 2024."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09235-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-09235-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09235-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T02:03:17Z","timestamp":1763172197000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-09235-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9235"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-09235-5","relation":{},"ISSN":["1745-6215"],"issn-type":[{"type":"electronic","value":"1745-6215"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"24 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial received ethical approval from the Ethics Committee of West China Hospital (Approval No. 2023 [1993]). Participants eligible for this trial will be thoroughly informed about the study\u2019s objectives, design, methodology, potential benefits, and risks. Written informed consent will be obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"507"}}